Summit Therapeu ADR (SMMT) Stock Price, Quote & News

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology

Sector: Healthcare

Phone: 305 203 2034

Website: www.smmttx.com

Address:

601 Brickell Key Drive, Suite 1000, Miami, United States

Carl81 Jan. 25 at 4:08 AM

$SMMT

0 · Reply

RadioIsotope25 Jan. 24 at 8:03 PM

If we see GY data linear absorption growth at 75 mci in next 30 days for rad202. We might be sitting on the next Pluvicto or Lutathera except for Her2 breast and esophageal cancers an $8 billion refractory Enhertu market. Would be multi-billion dollar stock like Summit $SMMT $RADX

4 · Reply

TruthBroker2 Jan. 24 at 12:32 AM

$SMMT

0 · Reply

quietpiggy Jan. 24 at 12:26 AM

$SMMT @Newyork_ you’re still getting ass pounded here I see 😂

2 · Reply

Reneejordan001 Jan. 23 at 9:48 PM

$SMMT Why doesn't Akeso buy us out?

1 · Reply

letstalk8 Jan. 23 at 8:54 PM

$SMMT I am pick up a few more here today thank you

0 · Reply

Magic8BallResponse Jan. 23 at 5:28 PM

$SMMT Investors frustrated they have not partnered up

2 · Reply

HitstheGreen Jan. 23 at 5:16 PM

$SMMT

0 · Reply

wgreystone Jan. 23 at 3:07 PM

$IBRX $SMMT has a licensed 2nd gen check point inhibitor drug in phase 3 with market cap of $12B. When Wall Street finally realizes the potential of Anktiva and NK cells, it will reprice $IBRX SP upwards

1 · Reply

TruthBroker2 Jan. 23 at 2:46 PM

$SMMT

0 · Reply

Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:15 AM EST - 13 days ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Jan 12, 2026, 6:00 AM EST - 13 days ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 9, 2026, 8:16 PM EST - 15 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 7:30 AM EST - 19 days ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 9:43 PM EST - 7 weeks ago

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 5:13 PM EST - 7 weeks ago

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 19, 2025, 4:26 AM EST - 2 months ago

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Nov 18, 2025, 12:38 PM EST - 2 months ago

Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 4:11 AM EST - 2 months ago

Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 9:00 AM EST - 2 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 4, 2025, 7:00 AM EST - 2 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 22, 2025, 8:00 AM EDT - 3 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Oct 20, 2025, 5:05 PM EDT - 3 months ago

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Oct 20, 2025, 2:35 PM EDT - 3 months ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 10:05 AM EDT - 3 months ago

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 6:45 AM EDT - 3 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 19, 2025, 10:30 AM EDT - 3 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 17, 2025, 7:00 AM EDT - 3 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 15, 2025, 7:00 AM EDT - 3 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Sep 24, 2025, 7:00 AM EDT - 4 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 22, 2025, 2:45 PM EDT - 4 months ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Sep 17, 2025, 10:54 PM EDT - 4 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 16, 2025, 4:31 PM EDT - 4 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 4 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 9, 2025, 9:12 AM EDT - 4 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Sep 8, 2025, 3:36 PM EDT - 4 months ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 8:28 AM EDT - 4 months ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:10 AM EDT - 4 months ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Sep 7, 2025, 6:08 AM EDT - 5 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 3:30 AM EDT - 5 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 3, 2025, 7:00 AM EDT - 5 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Aug 27, 2025, 2:43 PM EDT - 5 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 14, 2025, 7:00 AM EDT - 5 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 11, 2025, 5:03 PM EDT - 5 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Jul 14, 2025, 3:00 PM EDT - 6 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 7 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 8 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 9:10 AM EDT - 8 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

May 30, 2025, 2:50 PM EDT - 8 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 9:27 AM EDT - 8 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:01 AM EDT - 8 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 6:00 AM EDT - 8 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Carl81 Jan. 25 at 4:08 AM

$SMMT

0 · Reply

RadioIsotope25 Jan. 24 at 8:03 PM

4 · Reply

TruthBroker2 Jan. 24 at 12:32 AM

$SMMT

0 · Reply

quietpiggy Jan. 24 at 12:26 AM

$SMMT @Newyork_ you’re still getting ass pounded here I see 😂

2 · Reply

Reneejordan001 Jan. 23 at 9:48 PM

$SMMT Why doesn't Akeso buy us out?

1 · Reply

letstalk8 Jan. 23 at 8:54 PM

$SMMT I am pick up a few more here today thank you

0 · Reply

Magic8BallResponse Jan. 23 at 5:28 PM

$SMMT Investors frustrated they have not partnered up

2 · Reply

HitstheGreen Jan. 23 at 5:16 PM

$SMMT

0 · Reply

wgreystone Jan. 23 at 3:07 PM

1 · Reply

TruthBroker2 Jan. 23 at 2:46 PM

$SMMT

0 · Reply

SmokeWagon Jan. 23 at 3:50 AM

$SMMT !!!

0 · Reply

Diefreeandsell Jan. 23 at 12:28 AM

$IBRX $XBI $SOXL @WTF and public float is only ~330,000,000!!! So what % is really short on this ongoing gamma squeeze? Hey $SMMT(nsclc drug licensed from china, ibrx owns it’s own tech) $ALT (glp-1 drug🤷‍♂️ any news?)

1 · Reply

share97 Jan. 22 at 11:52 PM

$SMMT summit unfortunately proves it only matters who you know, not what you know. Thank you for your attention to this matter! $MAIA lol

1 · Reply

TruthBroker2 Jan. 22 at 9:29 PM

$SMMT

0 · Reply

Magic8BallResponse Jan. 22 at 9:03 PM

$SMMT Bob sells this after approval #1

0 · Reply

BigBeardTrader Jan. 22 at 7:41 PM

$SMMT 216 Price Target? https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/a-look-at-summit-therapeutics-smmt-valuation-after-ivonescim

1 · Reply

TXcountry Jan. 22 at 7:25 PM

$SMMT looking for $20,$25,$30 before 🧨🚀🚀🚀🚀🚀

0 · Reply

SmokeWagon Jan. 22 at 6:45 PM

$SMMT !

0 · Reply

Magic8BallResponse Jan. 22 at 5:44 PM

$SMMT Bob will get it done!

0 · Reply

Stbruce1978 Jan. 22 at 4:21 PM

$SMMT Useful chart from a research note from Guggenheim on another firm entering the space. Ivo is by far the leader in the space.

0 · Reply

TruthBroker2 Jan. 22 at 2:21 PM

$PLSE $SMMT 💰

0 · Reply

BigBeardTrader Jan. 22 at 2:20 PM

$SMMT Perspective: Comparing these as equals is misleading and ignores market size and future revenue potential.

0 · Reply

Market Cap	12.72B
Revenue (ttm)	0.00
Net Income (ttm)	-221.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,083,500
Avg Vol	2,594,464
Day's Range	N/A - N/A
Shares Out	771.15M
Stochastic %K	20%
Beta	-1.51
Analysts	Strong Sell
Price Target	$34.07